Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity

Suah Yang, Man Kyu Shim, Woo Jun Kim, Jiwoong Choi, Gi Hoon Nam, Jeongrae Kim, Jinseong Kim, Yujeong Moon, Han Young Kim, Jooho Park, Yoon Park, In San Kim, Ju Hee Ryu, Kwangmeyung Kim

Research output: Contribution to journal › Article › peer-review

94 Scopus citations

Fingerprint

Dive into the research topics of 'Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology

Biochemistry, Genetics and Molecular Biology